World J Mens Health.  2018 Jan;36(1):50-56. 10.5534/wjmh.17014.

Prevalence of Metabolic Syndrome and Associations with Lipid Profiles in Iranian Men: A Population-Based Screening Program

• Mohammadbeigi A
• Farahani H
• Moshiri E
• Sajadi M
• Ahmadli R
• Afrashteh
• Khazaei S
• Ansari H

• KMID: 2399171
• DOI: http://doi.org/10.5534/wjmh.17014

Abstract

PURPOSE
Metabolic syndrome (MS) is characterized by a collection of interdependent disorders, including abdominal obesity, dyslipidemia, hyperglycemia, hypertension, and diabetes. The current study aimed to estimate the prevalence of MS in Qom, Iran.
MATERIALS AND METHODS
A population-based screening program was conducted in the city of Qom, in 845 urban adult men over 25 years old in 2014. Abdominal obesity, fasting blood glucose (FBG), blood pressure, and the serum lipid profile were measured in subjects after fasting for at least 8 hours. MS was defined according to the Adult Treatment Panel III criteria. Data were analyzed using the chi-square test, t-test, and multiple logistic regression.
RESULTS
The overall prevalence of MS was 23.0%, and the most common prevalent metabolic abnormalities associated with MS were low high-density lipoprotein cholesterol (< 40 mg/dL) in 34.3% of subjects, a waist circumference >102 cm in 33.9%, blood pressure ≥130/85 mmHg in 27.6%, fasting triglycerides (TG) ≥150 mg/dL in 25%, and FBG ≥110 mg/dL in 20.6%. A FBG level ≥110 mg/dL (odds ratio [OR]=4.85; 95% confidence interval [CI], 2.14~8.24), dyslipidemia (OR=3.51; 95% CI, 2.10~5.89), and a fasting TG ≥150 mg/dL were the most important factors contributing to MS.
CONCLUSIONS
The prevalence of MS in men in Qom was higher than has been reported in other countries, but it was lower than the mean values that have been reported elsewhere in Iran. FBG was the most important factor contributing to MS, and all elements of the lipid profile showed important associations with MS.

Keyword

Cholesterol; Hyperlipidemias; Iran; Lipid metabolism disorders; Lipoproteins; Prevalence

MeSH Terms

Adult
Blood Glucose
Blood Pressure
Cholesterol
Dyslipidemias
Fasting
Humans
Hyperglycemia
Hyperlipidemias
Hypertension
Iran
Lipid Metabolism Disorders
Lipoproteins
Logistic Models
Male
Mass Screening*
Obesity, Abdominal
Prevalence*
Triglycerides
Waist Circumference
Blood Glucose
Cholesterol
Lipoproteins
Triglycerides

Reference

1. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24:683–689. PMID: 11315831.

2. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49:403–414. PMID: 17258085.

3. Hadaegh F, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F. Prevalence of metabolic syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions and their association with coronary heart disease in an elderly Iranian population. Ann Acad Med Singapore. 2009; 38:142–149. PMID: 19271043.

4. Giampaoli S, Stamler J, Donfrancesco C, Panico S, Vanuzzo D, Cesana G, et al. The metabolic syndrome: a critical appraisal based on the CUORE epidemiologic study. Prev Med. 2009; 48:525–531. PMID: 19344739.

5. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract. 2007; 77:251–257. PMID: 17234299.

6. Salaroli LB, Barbosa GC, Mill JG, Molina MC. Prevalence of metabolic syndrome in population-based study, Vitória, ES-Brazil. Arq Bras Endocrinol Metabol. 2007; 51:1143–1152. PMID: 18157391.

7. Amirkalali B, Fakhrzadeh H, Sharifi F, Kelishadi R, Zamani F, Asayesh H, et al. Prevalence of metabolic syndrome and its components in the Iranian adult population: a systematic review and meta-analysis. Iran Red Crescent Med J. 2015; 17:e24723. PMID: 26756015.

8. Topić E, Brguljam PM, Blaton V. New trends in classification, monitoring and management of metabolic syndrome. In : The 6th FESCC Continuous Postgraduate Course in Clinical Chemistry; 2016 Nov 11–12; Dubrovnik, Croatia.

9. Bender R, Jöckel KH, Richter B, Spraul M, Berger M. Body weight, blood pressure, and mortality in a cohort of obese patients. Am J Epidemiol. 2002; 156:239–245. PMID: 12142258.

10. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care. 2009; 32:1092–1097. PMID: 19279302.

11. Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J Public Health. 2014; 43:1275–1283. PMID: 26175982.

12. Davari RD, Khoshnood A. Evaluation of abdominal obesity prevalence in diabetic patients and relationships with metabolic syndrome factors. Int J Endocrinol Metab. 2010; 3:143–146.

13. Mohammadbeigi A, Moshiri E, Mohammadsalehi N, Ansari H, Ahmadi A. Dyslipidemia prevalence in Iranian adult men: the impact of population-based screening on the detection of undiagnosed patients. World J Mens Health. 2015; 33:167–173. PMID: 26770936.

14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497. PMID: 11368702.

15. Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, et al. Prevalence of dyslipidemia among Korean adults: Korea national health and nutrition survey 1998-2005. Diabetes Metab J. 2012; 36:43–55. PMID: 22363921.

16. Sharifi F, Mousavinasab SN, Saeini M, Dinmohammadi M. Prevalence of metabolic syndrome in an adult urban population of the west of Iran. Exp Diabetes Res. 2009; DOI: 10.1155/2009/136501. [Epub].

17. Azimi-Nezhad M, Herbeth B, Siest G, Dadé S, Ndiaye NC, Esmaily H, et al. High prevalence of metabolic syndrome in Iran in comparison with France: what are the components that explain this? Metab Syndr Relat Disord. 2012; 10:181–188. PMID: 22283632.

18. Zabetian A, Hadaegh F, Sarbakhsh P, Azizi F. Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study. BMC Public Health. 2009; 9:138. PMID: 19435528.

19. Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F. High prevalence of the metabolic syndrome in Iranian adolescents. Obesity (Silver Spring). 2006; 14:377–382. PMID: 16648607.

20. Gholipour M, Tabrizi A, Kazemnegad A. Prevalce of metabolic syndrome and its relationship with obesity indexes. Iran J Diabetes Lipid Disord. 2013; 12:324–334.

21. Azizi F, Hadaegh F, Khalili D, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Arch Iran Med. 2010; 13:426–428. PMID: 20804311.

22. Hassanzadeh J, Mohammadbeigi A, Eshrati B, Moemenbellah-Fard MD. Estimation of the regional burden of non-communicable diseases due to obesity and overweight in Markazi province, Iran, 2006-2007. J Cardiovasc Dis Res. 2012; 3:26–31. PMID: 22346142.

23. Eshrati B, Hasanzadeh J, Beigi AM. Calculation of population attributable burden of excess weight and obesity to non-contagious diseases in Markazi province of Iran. Koomesh. 2009; 11:83–90.

24. Abolfazl M, Hamidreza TS, Narges M, Maryam Y. Gestational diabetes and its association with unpleasant outcomes of pregnancy. Pak J Med Sci. 2008; 24:566–570.

25. Heidari S, Rezaei M, Sajadi M, Ajorpaz NM, Koenig HG. Religious practices and self-care in Iranian patients with type 2 diabetes. J Relig Health. 2017; 56:683–696. PMID: 27783261.